Abstract:RNA editing offers the opportunity to introduce either stable or transient modifications to nucleic acid sequence without permanent off-target effects, but installation of arbitrary edits into the transcriptome is currently infeasible. Here, we describe Programmable RNA Editing & Cleavage for Insertion, Substitution, and Erasure (PRECISE), a versatile RNA editing method for writing RNA of arbitrary length and sequence into existing pre-mRNAs via 5′ or 3′ trans-splicing. In trans-splicing, an exogenous template is introduced to compete with the endogenous pre-mRNA, allowing for replacement of upstream or downstream exon sequence. Using Cas7-11 cleavage of pre-mRNAs to bias towards editing outcomes, we boost the efficiency of RNA trans-splicing by 10–100 fold, achieving editing rates between 5–50% and 85% on endogenous and reporter transcripts, respectively, while maintaining high-fidelity. We demonstrate PRECISE editing across 11 distinct endogenous transcripts of widely varying expression levels, showcasing more than 50 types of edits, including all 12 possible transversions and transitions, insertions ranging from 1 to 1,863 nucleotides, and deletions. We show high efficiency replacement of exon 4 of MECP2, addressing most mutations that drive the Rett Syndrome; editing of SHANK3 transcripts, a gene involved in Autism; and replacement of exon 1 of HTT, removing the hallmark repeat expansions of Huntington′s disease. Whole transcriptome sequencing reveals the high precision of PRECISE editing and lack of off-target trans-splicing activity. Furthermore, we combine payload engineering and ribozymes for protein-free, high-efficiency trans-splicing, with demonstrated efficiency in editing HTT exon 1 via AAV delivery. We show that the high activity of PRECISE editing enables editing in non-dividing neurons and patient-derived Huntington’s disease fibroblasts. PRECISE editing markedly broadens the scope of genetic editing, is straightforward to deliver over existing gene editing tools like prime editing, lacks permanent off-targets, and can enable any type of genetic edit large or small, including edits not otherwise possible with existing RNA base editors, widening the spectrum of addressable diseases.

Precision Transcriptome Editing

Programmable RNA writing with trans-splicing

Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification.

Utilization of TALEN and CRISPR/Cas9 Technologies for Gene Targeting and Modification

Precision epigenetic editing: Technological advances, enduring challenges, and therapeutic applications

Prime editing for precise and highly versatile genome manipulation

Precision genome editing using cytosine and adenine base editors in mammalian cells

Base editing: precision chemistry on the genome and transcriptome of living cells

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

Precision RNA base editing with engineered and endogenous effectors

Precision Control of Cell Type‐Specific Behavior via RNA Sensing and Editing

Enhancing the RNA Engineering Toolkit

CRISPR-Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics

Precise genome-editing in human diseases: mechanisms, strategies and applications

Precise transcript targeting by CRISPR-Csm complexes

Exonuclease editor promotes precision of gene editing in mammalian cells

Precision Genome Editing Techniques in Gene Therapy: Current State and Future Prospects

RNA Base Editors: the Emerging Approach of RNA Therapeutics.

Prime editing: Its systematic optimization and current applications in disease treatment and agricultural breeding

Design and application of the transformer base editor in mammalian cells and mice

Deconstructing cancer with precision genome editing